头孢他啶对囊性纤维化患者分离出的铜绿假单胞菌的体外药效学
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
作者信息
Manduru M, Mihm L B, White R L, Friedrich L V, Flume P A, Bosso J A
机构信息
Anti-Infective Research Laboratory, College of Pharmacy, Medical University of South Carolina, Charleston 29245-2303, USA.
出版信息
Antimicrob Agents Chemother. 1997 Sep;41(9):2053-6. doi: 10.1128/AAC.41.9.2053.
Abstract
The concentration/MIC (C/MIC) ratio maximizing the bactericidal activity of ceftazidime against 10 Pseudomonas aeruginosa isolates from cystic fibrosis patients was identified. Bactericidal activity was assessed by determining the percent difference in the area under the killing curve at each C/MIC ratio for all of the isolates from that of their growth control. The percent effect at each C/MIC ratio was fitted to a sigmoidal Emax model with maximum bactericidal activity defined as the C/MIC ratio that produced an effect that was 90% of the Emax. Our results suggest that at least some isolates may require higher C/MIC ratios than previously reported for maximal activity.
摘要
确定了使头孢他啶对来自囊性纤维化患者的10株铜绿假单胞菌分离株杀菌活性最大化的浓度/最低抑菌浓度（C/MIC）比值。通过测定在每个C/MIC比值下所有分离株的杀菌曲线下面积与其生长对照的杀菌曲线下面积的百分比差异来评估杀菌活性。将每个C/MIC比值下的效应百分比拟合到一个S形Emax模型中，将最大杀菌活性定义为产生的效应为Emax的90%的C/MIC比值。我们的结果表明，至少一些分离株可能需要比先前报道的更高的C/MIC比值才能达到最大活性。
相似文献
1
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.头孢他啶对囊性纤维化患者分离出的铜绿假单胞菌的体外药效学
Antimicrob Agents Chemother. 1997 Sep;41(9):2053-6. doi: 10.1128/AAC.41.9.2053.
2
In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.美罗培南、亚胺培南、头孢吡肟和头孢他啶对囊性纤维化患者分离出的铜绿假单胞菌的体外活性。
J Antimicrob Chemother. 2000 Jun;45(6):899-901. doi: 10.1093/jac/45.6.899.
3
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
Pathol Biol (Paris). 2003 Apr;51(3):135-42. doi: 10.1016/s0369-8114(03)00023-3.
4
The in-vitro activity of three anti-pseudomonal cephalosporins against isolates from patients with cystic fibrosis.
J Antimicrob Chemother. 1981 Sep;8 Suppl B:175-8. doi: 10.1093/jac/8.suppl_b.175.
5
Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method.
Antimicrob Agents Chemother. 1997 Nov;41(11):2527-32. doi: 10.1128/AAC.41.11.2527.
6
Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.囊性纤维化患者中铜绿假单胞菌对头孢吡肟和头孢他啶的敏感性
Pharmacotherapy. 2001 Nov;21(11):1320-4. doi: 10.1592/phco.21.17.1320.34420.
7
8
Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.在药效学感染模型中，针对铜绿假单胞菌临床分离株，评估头孢吡肟的几种给药方案，并对肾功能进行各种模拟。
Antimicrob Agents Chemother. 1999 Jan;43(1):129-33. doi: 10.1128/AAC.43.1.129.
9
Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.头孢他啶阿维巴坦对从囊性纤维化患者中分离出的耐多药非发酵革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02688-16. Print 2017 Apr.
10
Activity of ceftazidime against Pseudomonas aeruginosa from bacteraemic and fibrocystic patients.
J Antimicrob Chemother. 1981 Sep;8 Suppl B:169-73. doi: 10.1093/jac/8.suppl_b.169.
引用本文的文献
1
Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.全球抗生素治疗方案规划和确定抗菌药物耐药目标面临的挑战：对世卫组织基本药物清单和 AWaRe 抗生素书籍剂量的影响。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0013923. doi: 10.1128/cmr.00139-23. Epub 2024 Mar 4.
2
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating resistance to meropenem.模拟危重症患者的药物处置，以评估针对美罗培南耐药性的有效 PK/PD 靶标。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0154123. doi: 10.1128/aac.01541-23. Epub 2024 Feb 6.
3
Antibiotics in anesthesia and critical care.麻醉与重症监护中的抗生素
Ann Transl Med. 2024 Feb 1;12(1):6. doi: 10.21037/atm-22-5585. Epub 2023 Dec 13.
4
Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.儿童和成人β-内酰胺类抗生素的剂量优化：一项系统评价。
Front Pharmacol. 2022 Sep 21;13:964005. doi: 10.3389/fphar.2022.964005. eCollection 2022.
5
A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.儿科患者中延长输注和持续输注β-内酰胺类药物的综述
J Pediatr Pharmacol Ther. 2022;27(3):214-227. doi: 10.5863/1551-6776-27.3.214. Epub 2022 Mar 21.
6
Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.接受间歇性高通量血液透析患者的透析后肠外抗菌治疗。
Drugs. 2021 Apr;81(5):555-574. doi: 10.1007/s40265-021-01469-2. Epub 2021 Feb 16.
7
Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.抗生素治疗囊性纤维化患者的药代动力学和药效学优化：当前证据、知识空白和未来方向。
Clin Pharmacokinet. 2021 Apr;60(4):409-445. doi: 10.1007/s40262-020-00981-0. Epub 2021 Jan 24.
8
The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome.越高越好？确定重症患者达到感染缓解并改善预后的最佳β-内酰胺目标。
J Intensive Care. 2020 Nov 23;8(1):86. doi: 10.1186/s40560-020-00504-w.
9
Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.β-内酰胺类抗生素持续输注与间断输注：临床前感染模型中细菌清除的系统评价和荟萃回归分析。
Clin Pharmacokinet. 2020 Oct;59(10):1237-1250. doi: 10.1007/s40262-020-00919-6.
10
Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.急性-on-慢性肝衰竭改变了接受持续血液透析的重症患者美罗培南的药代动力学：一项观察性研究。
Ann Intensive Care. 2020 Apr 22;10(1):48. doi: 10.1186/s13613-020-00666-8.
本文引用的文献
1
Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.持续输注β-内酰胺类抗生素是否值得？——疗效及药代动力学考量
J Antimicrob Chemother. 1996 Jul;38(1):5-15. doi: 10.1093/jac/38.1.5.
2
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.头孢他啶持续输注与间歇给药用于疑似革兰阴性菌感染的重症患者的比较。
Antimicrob Agents Chemother. 1996 Mar;40(3):691-5. doi: 10.1128/AAC.40.3.691.
3
Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.头孢他啶的血清杀菌活性：持续输注与间歇注射对比
Antimicrob Agents Chemother. 1996 Jan;40(1):61-4. doi: 10.1128/AAC.40.1.61.
4
Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.在体外药代动力学模型中持续和间歇输注头孢他啶期间对铜绿假单胞菌的杀灭作用。
Antimicrob Agents Chemother. 1994 May;38(5):931-6. doi: 10.1128/AAC.38.5.931.
5
Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home.
Ther Drug Monit. 1994 Aug;16(4):341-8. doi: 10.1097/00007691-199408000-00002.
6
Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.
Eur J Clin Microbiol Infect Dis. 1995 Mar;14(3):188-92. doi: 10.1007/BF02310354.
7
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.在体外感染模型中，头孢他啶单独持续输注或间歇推注以及与每日单次剂量阿米卡星联合应用对铜绿假单胞菌的药效学研究。
Antimicrob Agents Chemother. 1995 Aug;39(8):1797-801. doi: 10.1128/AAC.39.8.1797.
8
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.理解剂量-效应关系：药代动力学-药效学模型的临床应用
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
9
Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo.β-内酰胺类抗生素在体外和体内药理反应的时间进程。
Eur J Clin Microbiol. 1984 Dec;3(6):592-7. doi: 10.1007/BF02013630.
10
Role for dual individualization with cefmenoxime.头孢甲肟双重个体化的作用。
Am J Med. 1984 Dec 21;77(6A):43-50. doi: 10.1016/s0002-9343(84)80074-1.
Zotero 插件